This is a working overview of Alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-24. Anything still debated is marked as such rather than presented as settled.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
In 1210, all Jewish householders in England were imprisoned in Bristol and a hefty levy of 60,000 or 66,000 marks was imposed on them. During the Second Barons' War, the city's archa was burned and the Jewish community was violently attacked. There was another attack in 1275, but without fatalities. The community was expelled with the rest of England's Jews in 1290. There is a surviving Jewish ritual bath, from this time period now known as Jacob's Well. First interpreted as a mikveh, this was subsequently re-evaluated as a Bet Tohorah, associated with the nearby Jewish cemetery at Jews Acre.
Diabetes mellitus is a metabolic disease that is characterized by chronic elevated blood glucose levels (hyperglycemia). Therefore, the main goal of diabetes management is to keep blood glucose levels within normal limits (or a diabetic target range) as often as possible. If diabetes is not well controlled, health challenges may develop. People with diabetes can measure blood glucose by various methods, such as with a glucose meter or a continuous glucose monitor, which monitors over several days. Long-term glucose levels (over 3 months) can also be measured by analysis of a blood sample. In addition to lifestyle modification, some individuals with type 2 diabetes may require medication to adequately control their blood glucose levels. Other goals of diabetes management are prevention or treatment of complications that can result from the disease itself and from its treatment.
== N == NAT – National Cancer Institute (NCI) – National Institute of Allergy and Infectious Diseases (NIAID) – National Institute of Child Health and Human Development (NICHD) – National Institutes of Health (NIH) – National Library of Medicine (NLM) – National Prevention Information Network (NPIN) – natural history study – natural killer cells (NK cells) – NCI – New Drug Application – nebulized – Nef – neoplasm – nephrotoxic – neuralgia – neurological complications of AIDS – neuropathy – neutralization – neutralizing antibody – neutralizing domain – neutropenia – neutrophil – New Drug Application (NDA) – New York Cares – NIAID – NICHD – night sweat – NIH – NK cell – NLM – NNRTI – non-Hodgkin's lymphoma (NHL) – non-nucleoside reverse transcriptase inhibitors (NNRTI) – non-steroidal anti-inflammatory drugs (NSAID) – NRTI – nucleic acid – nucleic acid test – nucleocapsid – nucleoli – nucleoside – nucleoside analog – nucleoside reverse transcriptase inhibitors (NRTI) – nucleotide – nucleotide analogs – nucleus – null cell
Sources: en.wikipedia.org
== Operations == Ecotutu provide solar-powered food storage for farmers in Nigeria. The company operates a ‘pay-as-you-chill’ storage service for fruit and vegetable farmers, using solar-powered evaporation technology in Nigeria. Ecotutu operates at multiple locations across states in Nigeria, offering cooling as a service in open markets and farm clusters.
=== January === The late 2000s recession has entered its second full year of existence. While many nations have managed to climb out of the recession, employment is still sparse and promises to remain so throughout 2010.
=== Etymology === The name "multiple sclerosis" is short for multiple cerebro-spinal sclerosis, which refers to the numerous glial scars (or sclerae – essentially plaques or lesions) that develop on the white matter of the brain and spinal cord.
Sources: en.wikipedia.org
=== United Kingdom === From 2013, the UK National Health Service (NHS) started offering shingles vaccination to elderly people. People aged either 70 or 79 on 1 September 2013, were offered the vaccine. People aged 71 to 78 on that date would only have an opportunity to have the shingles vaccine after reaching the age of 79. The original intention was for people aged between 70 and 79 to be vaccinated, but the NHS later said that the vaccination program was being staggered as it would be impractical to vaccinate everyone in their 70s in a single year. In 2021, vaccination against shingles is available on the NHS to people aged 70 to 79. Vaccination is with single-dose Zostavax, except for people for whom Zostavax is deemed unsuitable, for example, with a condition that affects the immune system, for whom two-dose Shingrix vaccine is recommended. The NHS stated "The shingles vaccine is not available on the NHS to anyone aged 80 or over because it seems to be less effective in this age group". Since 2023, the shingles vaccines is being offered to healthy people turning 65.
React based in Sweden has produced informative material on AMR for the general public. Videos are being produced for the general public to generate interest and awareness. The Irish Department of Health published a National Action Plan on Antimicrobial Resistance in October 2017. The Strategy for the Control of Antimicrobial Resistance in Ireland (SARI), Iaunched in 2001 developed Guidelines for Antimicrobial Stewardship in Hospitals in Ireland in conjunction with the Health Protection Surveillance Centre, these were published in 2009. Following their publication a public information campaign 'Action on Antibiotics' was launched to highlight the need for a change in antibiotic prescribing. Despite this, antibiotic prescribing remains high with variance in adherence to guidelines. The United Kingdom published a 20-year vision for antimicrobial resistance that sets out the goal of containing and controlling AMR by 2040. The vision is supplemented by a 5-year action plan running from 2019 to 2024, building on the previous action plan (2013–2018).
== Usage == This technique can be used to identify the genomic footprint of inbreeding in conservation programs, as organisms that have undergone recent inbreeding will exhibit long runs of homozygosity. For example, the step-wise reintroduction strategy of the Alpine Ibex in the Swiss Alps created several strong population bottlenecks that reduced the genetic diversity of the newly introduced individuals. The effect of inbreeding in the resulting sub-populations could be studied by measuring the runs of homozygosity in different individuals. In clinical laboratory testing, the detection of ROH in itself does not indicate a particular genetic disorder but indicates an increased risk of autosomal recessive inherited diseases. As ROHs smaller than 3 Mb spread throughout the genome are common even in outbred populations, these segments were usually thought to not be important enough to report. Large ROH can be indicative of uniparental isodisomy with follow-up testing to rule out false positives, there is currently no consistent reporting standards among different laboratories. ROH can be used to detect the possibility of incest in humans.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.